explore -WSS

explore

author：leisure time 2025-08-12 06:38:09 - browse：9434

Terry Horgan pictured at home -- coverage from STAT — Terry Horgan in his family's Montour Falls, N.Y., home, in an undated photo. Kate Collins/The Journal via AP

Last October, a 27-year-old man with Duchenne muscular dystrophy died after receiving a CRISPR-based treatment custom built to treat his particular genetic mutation.

Results of a detailed investigation released on Wednesday suggest that the patient, Terry Horgan, likely died of a previously undocumented adverse effect of the virus used to deliver the CRISPR machinery to his cells.

These viruses, known as adeno-associated viruses, or AAVs, are used in several approved drugs and hundreds of clinical trials to deliver genes into patients, because they are generally benign. But at high doses they can cause side effects and, occasionally, deaths through one of several mechanisms, such as directly injuring the liver or triggering a type of immune response known as complement activation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Surgery pushed Ben Carson to fame

focus

hotspot

WSS

Crinetics acromegaly drug succeeds in late

A new House health package & hospitals’ new site

Ethical issues complicate the benefits of medical crowdfunding

A single Democrat is willing to weaken Medicare negotiation power

Listen: Biogen's potential pivot, & Illumina's next chapter

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

explore

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

How to fix cancer clinical trials' diversity problem

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The (many) problems with a new study criticizing cancer screening

Duchenne breakthrough therapy leaves behind pioneering families

Ethical issues complicate the benefits of medical crowdfunding

The cancer drug shortage isn’t new — and neither are the solutions

Why Novartis is going to walk from its acquisition of MorphoSys

Jerome Adams on the need for new antivirals for Covid

AstraZeneca stays mum on Medicare drug pricing negotiations

leisure time

NIH nominee Bertagnolli will get October confirmation hearing

A protest over insulin prices is seen as a fight for life

The CDC's new social media misinformation war

'Make People Better': The CRISPR babies story you probably don't know

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

How to fix cancer clinical trials' diversity problem

focus

focus

hotspot

entertainment